Last update 28 Sep 2024
Degarelix Acetate
Last update 28 Sep 2024
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms Degarelix acetate (USAN), Degarelix acetate hydrate, UGLYPEPTIDE-1 + [7] |
Target |
Mechanism GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (24 Dec 2008), |
Regulation- |
Login to view First Approval Timeline
Structure
Molecular FormulaC84H109ClN18O19 |
InChIKeyQMBXFMRFTMPFEY-YECCWIQASA-N |
CAS Registry934246-14-7 |
Gene Sequence
Sequence Code 26246295
Source: *****
Related
152
Clinical Trials associated with Degarelix AcetateA Phase I, Open-label, Multi-center Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in de Novo Metastatic to Lymph Nodes Prostate Cancer
A Prospective, Randomized, Open-label, Multi-centre, Phase II Trial Evaluating IDC/SChLAP1 as a Biomarker for Prediction of Response to Intensified Combined Modality Treatment
100 Clinical Results associated with Degarelix Acetate
Login to view more data
100 Translational Medicine associated with Degarelix Acetate
Login to view more data
100 Patents (Medical) associated with Degarelix Acetate
Login to view more data
313
Literatures (Medical) associated with Degarelix Acetate10 Sep 2024INTERNATIONAL JOURNAL OF UROLOGY
Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high-risk prostate cancer who underwent robot-assisted radical prostatectomy.
Article
Author: Nagoshi, Akihiko ; Yamamoto, Akihiro ; Murata, Shiori ; Kokubun, Hidetoshi ; Akagi, Naoki ; Abe, Yohei ; Yamasaki, Toshinari ; Hagimoto, Hiroki ; Shibasaki, Noboru ; Tsutsumi, Naofumi ; Kawakita, Mutsushi ; Igarashi, Atsushi ; Fujiwara, Tasuku ; Hattori, Yuto ; Mine, Yuta ; Kambe, Takanari
OBJECTIVES:
The objective of this study is to evaluate the safety and efficacy of neoadjuvant degarelix acetate and low-dose estramustine phosphate for high-/very high-risk prostate cancer.
METHODS:
Overall, 187 patients diagnosed with National Comprehensive Cancer Network high-/very high-risk cTanyN0M0 localized prostate cancer who consented to undergo robot-assisted radical prostatectomy after receiving neoadjuvant chemohormonal therapy for 6 months were prospectively enrolled between December 2017 and March 2023. Adverse events, perioperative and histopathological outcomes, and biochemical recurrence-free survival rates were examined. Survival analysis compared the estramustine phosphate completion and reduction groups.
RESULTS:
Thirty-six patients discontinued neoadjuvant therapy in <5 months owing to adverse events (n = 34) or other reasons (n = 2). Eleven were excluded for being in the postoperative castration range. Of the 140 patients who underwent surgery, 124 continued with two tablets of estramustine phosphate and 16 with one tablet. Overall, 82 patients were very high-risk. Histopathological outcomes were significantly worse in the very high-risk group than those in the high-risk group. Very high-risk status and estramustine phosphate reduction were significant factors in biochemical recurrence in multivariate analysis. The biochemical recurrence-free survival rate in very high-risk patients was significantly lower in the estramustine phosphate dose reduction group than in the completion group but not significant in high-risk patients. Major adverse events were anemia (n = 174), elevated transaminase levels (n = 68), and deep vein thrombosis (n = 24). Severe adverse events included acute coronary syndrome (n = 4) and pulmonary embolism (n = 3).
CONCLUSIONS:
Dose compliance with estramustine phosphate predicted biochemical recurrence in patients with very high-risk prostate cancer undergoing robot-assisted radical prostatectomy with neoadjuvant chemohormonal therapy.
01 Sep 2024UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Testosterone recovery after androgen deprivation therapy
Article
Author: Neill, Clayton ; Bennett, Richard ; Ho, Austin Y ; Li, Yutai ; Suk-Ouichai, Chalairat ; Ross, Ashley E ; Morgans, Alicia K. ; Kumar, Sai Kaushik Shankar Ramesh ; Ross, Ashley E. ; Li, Eric V. ; Patel, Hiten D. ; Ho, Austin Y. ; Schaeffer, Edward M. ; Schaeffer, Edward M ; Morgans, Alicia K ; Li, Eric V ; Patel, Hiten D ; Suk-ouichai, Chalairat
PURPOSE:
Finite courses of androgen deprivation therapy (ADT) are often utilized in men undergoing treatment for prostate cancer. Previous evidence suggests that timing of testosterone (T) recovery can be variable after ADT. Recently, an oral gonadotropin releasing-hormone (GnRH) antagonist, relugolix, has demonstrated more rapid T recovery than injectable GnRH agonists such as leuprolide. In this study, we sought to evaluate patient characteristics associated with T recovery in patients undergoing ADT of defined duration.
MATERIALS AND METHODS:
The Northwestern Enterprise Data Warehouse was queried for men with prostate cancer who completed a course of ADT and subsequently had a testosterone lab performed. Testosterone recovery was evaluated for levels that reached above castrate (T > 50 ng/dl), partial recovery (T > 150 ng/dl), and full recovery (T ≥ 300 ng/dl).
RESULTS:
388 men who received finite courses of ADT were identified (348 receiving leuprolide, 36 receiving relugolix, and 4 receiving degarelix). In multivariable Cox regression analysis, men who were prescribed GnRH antagonists (HR = 3.74, CI = 2.53-5.53, P ≤ 0.001) and who were younger (HR for 1 year increase in age = 0.96, CI = 0.95-0.98, P < 0.001) were more likely to achieve partial recovery. In a subgroup analysis, men who received extended ADT courses (>12 months) with a GnRH agonist had lower rates of partial T recovery (HR = 0.58, CI = 0.41-0.81, P = 0.001).
CONCLUSION:
T recovery after ADT is variable with roughly one sixth of men remaining castrate. GnRH antagonist use and younger age are associated with higher rates of T recovery after ADT. Longer ADT courses were associated with worse T recovery rates.
01 Aug 2024Clinical Genitourinary Cancer
Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm
Review
Author: Sammarco, Enrico ; Di Vita, Rosanna ; Paolieri, Federico ; Coccia, Natalia ; Bonato, Adele ; Roviello, Giandomenico ; Serafin, Debora ; Salfi, Alessia ; Manfredi, Fiorella ; Bloise, Francesco ; Sisani, Michele ; Oliveri, Maria ; Zatteri, Luca ; Catalano, Martina ; Dima, Giovanni ; Galli, Luca ; Ferrari, Marco ; Carli, Chiara ; Doni, Laura
Prostate carcinoma (PC), the second most diagnosed cancer globally, saw approximately 1,414,000 new cases in 2020, with 17% being de novo metastatic. In these cases, the 5-year relative survival rate is 32%. Metastatic hormone-sensitive prostate cancer (mHSPC) includes those with metastatic disease at initial diagnosis or after initial therapy without long-term androgen deprivation therapy (ADT), eventually progressing to castration-resistant prostate cancer (CRPC). The established therapeutic principle of ADT has persisted for 80 years, with luteinizing hormone-releasing hormone (LHRH) agonists like leuprorelin being commonly used. LHRH antagonists, such as degarelix, have also emerged. Recent advances in mHSPC treatment involve combination strategies with drugs proven effective in CRPC, considering prognostic factors like disease volume and presentation. This review outlines pivotal trials leading to drug approvals in mHSPC and proposes a treatment decision algorithm for the same, based on statement from the Tuscan Interdisciplinary Uro-Oncological Group. A multidisciplinary approach is crucial to tailor treatment intensity and weigh risks and benefits effectively.
2
News (Medical) associated with Degarelix Acetate13 Jun 2023
Drug ApprovalPhase 3VaccineClinical ResultGene Therapy
20 Jun 2022
Generic DrugBiosimilarImmunotherapyRadiation TherapyASCO
100 Deals associated with Degarelix Acetate
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Castration-sensitive prostate cancer | CH | 12 Feb 2010 | |
| Hormone-dependent prostate cancer | EU | 17 Feb 2009 | |
| Hormone-dependent prostate cancer | IS | 17 Feb 2009 | |
| Hormone-dependent prostate cancer | LI | 17 Feb 2009 | |
| Hormone-dependent prostate cancer | NO | 17 Feb 2009 | |
| Prostatic Cancer | US | 24 Dec 2008 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Prostate Carcinoma | Phase 3 | US | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | CA | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | CZ | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | FI | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | FR | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | DE | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | GR | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | PL | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | RU | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | SK | 19 Apr 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 56 | stereotactic body radiosurgery (SBRT)+Degarelix (Degarelix in Conjunction With Stereotactic Body Radiosurgery) | svknjlqage(dyvbswyjgy) = twvrdfhgdg azfbririor (kbyknqlyhq, lzcpvoglmq - ieswsqchzi) View more | - | 28 Aug 2024 | ||
stereotactic body radiosurgery (SBRT) (Stereotactic Body Radiosurgery (SBRT)) | svknjlqage(dyvbswyjgy) = hrcyfdmfpm azfbririor (kbyknqlyhq, hpboxjabfs - xxglcblzkp) View more | ||||||
Phase 3 | 545 | (Degarelix 240 mg/80 mg) | yyjxzqmjll(bmpzguyiwf) = rvajajvxhg zyfuhwzmiv (wcmvzgvehy, zycymxxmkp - hwyiiarybc) View more | - | 29 Jun 2022 | ||
(Leuprolide 22.5 mg) | yyjxzqmjll(bmpzguyiwf) = tcusflgaly zyfuhwzmiv (wcmvzgvehy, ebeyrcbxyc - srkktiedhc) View more | ||||||
Phase 2 | 96 | (Placebo + BSC) | xqutkvoiia(htlubgzjjy) = bjzhwejqig ghzezalnjy (goptvegbzu, bsvcrjmaqg - ecalfldzvu) View more | - | 06 Jun 2022 | ||
(Degarelix + BSC) | xqutkvoiia(htlubgzjjy) = fbolemmuql ghzezalnjy (goptvegbzu, zgrjvpjmyb - gajhqkcpwk) View more | ||||||
Not Applicable | 124 | ybafkbzpif(awewwghijf) = 42 adverse events (AEs) were reported in 22 patients: degarelix-related AEs were reported in 4.4% of patients chfjzoiayq (fvuteouvfe ) | - | 16 Feb 2022 | |||
Phase 2 | 124 | (Abiraterone Acetate) | cslqgewwwp(agrhamultg) = kpmzwykrtc zvwxbfcqvc (qulscgdpkm, tnkeiepucj - bzuyxhinxd) View more | - | 19 Nov 2021 | ||
(Abiraterone Acetate and Degarelix) | cslqgewwwp(agrhamultg) = ppumprulfc zvwxbfcqvc (qulscgdpkm, bzsfdxydth - csbgyvvhvi) View more | ||||||
Phase 3 | 545 | axfxjszhos(asbxvxxjne) = kbsnxglynr dtyvaerbtp (vdedlbmpld ) | Similar | 19 Oct 2021 | |||
Leuprolide | axfxjszhos(asbxvxxjne) = drvpsdwujv dtyvaerbtp (vdedlbmpld ) | ||||||
Not Applicable | 11 | hkrmcdaiwd(xdedlugzyt): RR = 0.8 (95% CI, 0.62 - 1.05) View more | - | 05 Aug 2021 | |||
Standard androgen suppression therapy | |||||||
Phase 2 | Metastatic Prostate Carcinoma First line | 50 | docetaxel+degarelix | acvdmcrzva(jfyilxznia) = beicbwjqyj yxweijyots (ioazwukpqz ) View more | Positive | 02 Mar 2021 | |
Phase 2 | 51 | (Arm A: Triptorelin + Letrozol) | hqvwrwvari(qutqvyrgqm) = pgvaedyoap jvkcjfbbdp (cwmcyrrodl, vekdlfaqmq - nmzufwsbyv) View more | - | 29 May 2019 | ||
hqvwrwvari(qutqvyrgqm) = bzdvitjixa jvkcjfbbdp (cwmcyrrodl, jgpsyznzst - jxygthhmip) View more | |||||||
Not Applicable | 12 | kocbyemtju(ktkqvvacgr) = qsltwyrdyd mbryifvmck (jjrdljowec, zcrnvtbcna - esaxrdfdgt) View more | - | 03 Apr 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free